Cabiralizumab (FPA008, Five Prime Therapeutics) recently completed Phase I/II trials to evaluate the safety, tolerability, and effectiveness of Cabiralizumab in diffuse TGCT.
While both DCC-3014 and Pexidartinib are molecule-based drugs (like many oral pills on market), this drug relies on a protein antibody that blocks CSF1 by holding onto it and preventing it from reaching TGCT and surrounding cells. This drug was given as an intravenous infusion for 30 minutes every 2-to-4 weeks.
By blocking CSF1, the tumor cannot grow and develop. This clinical trial took place at 12 different global clinical locations.